Efaproxiral

Lung Cancer

Spectrum Pharmaceuticals, IncSmall moleculePhase 3Dormant

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 65/ 100

Competitive context

304 Active assets in the Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Carboplatin SystImmune Inc.	Phase 4	BB
CIS-DIAMMINEDICHLOROPLATINUM II University of Vermont	Phase 4	BB
PROPOFOL Kaohsiung Medical University Chung-Ho Memorial Hospital	Phase 4	BB
ETOPOSIDE SystImmune Inc.	Phase 3	BB
Nivolumab University of Chicago	Phase 4	BB

View all 50 →

Same molecule, other indications

Efaproxiral is also rated in:

metastatic neoplasmDormant

B

Indicative ·

62 / 100

breast cancerDormant

CCC

Indicative ·

52 / 100

central nervous system neoplasmDormant

CCC

Indicative ·

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.